DiaMedica Therapeutics (DMAC) BidaskScore is downgraded to Strongly Sold

DiaMedica Therapeutics, Inc.

The BidaskScore of DiaMedica Therapeutics Inc. DMACDMAC shows that the shares of the company are now DMACStrongly Bought Strongly Sold by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Strongly Sold since September 25.

Here are the BidAskScore of other related companies in the Biotechnology sector:

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

DiaMedica Therapeutics, Inc.

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.